melatonin has been researched along with Hormone-Dependent Neoplasms in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin inhibits the proliferation of estrogen receptor alpha (ERalpha)-positive (MCF-7), but not ERalpha-negative (MDA-MB-231) breast cancer cells." | 7.71 | MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. ( Collins, AR; Dai, J; Dubocovich, ML; Hill, SM; Yuan, L, 2002) |
| "The pineal hormone, melatonin, was examined for its capacity to modulate the proliferation of a panel of human breast cancer cell lines." | 7.68 | The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. ( Blask, DE; Hill, SM; Muraoka, H; Simon, MA; Spriggs, LL, 1992) |
| "Melatonin exerts oncostatic effects on different kinds of tumors, especially on hormone-dependent breast cancer." | 4.84 | Melatonin as a selective estrogen enzyme modulator. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2008) |
| "The authors have shown that, via activation of its MT1 receptor, melatonin modulates the transcriptional activity of various nuclear receptors and the proliferation of both ER alpha+ and ER alpha- human breast cancer cells." | 3.75 | Molecular mechanisms of melatonin anticancer effects. ( Duplessis, T; Frasch, T; Hill, SM; Mao, L; Xiang, S; Yuan, L, 2009) |
| "Melatonin inhibits the proliferation of estrogen receptor alpha (ERalpha)-positive (MCF-7), but not ERalpha-negative (MDA-MB-231) breast cancer cells." | 3.71 | MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. ( Collins, AR; Dai, J; Dubocovich, ML; Hill, SM; Yuan, L, 2002) |
| " Two such oncostatic agents, melatonin and retinoic acid, have been shown to suppress the growth of hormone-responsive breast cancer." | 3.70 | A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells. ( Ayettey, S; Chen, I; Cohn, CS; Duffy, L; Eck, KM; Hill, SM; Ram, PT; Reed, JC; Yuan, L, 1998) |
| "The melatonin hypothesis states that excess exposure to environmental light may contribute to breast cancer risks via impaired pineal secretion of melatonin." | 3.70 | Does winter darkness in the Artic protect against cancer? The melatonin hypothesis revisited. ( Erren, TC; Piekarski, C, 1999) |
| "The pineal hormone, melatonin, was examined for its capacity to modulate the proliferation of a panel of human breast cancer cell lines." | 3.68 | The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. ( Blask, DE; Hill, SM; Muraoka, H; Simon, MA; Spriggs, LL, 1992) |
| "The effects of the pineal hormone, melatonin, and of pinealectomy on the incidence of mammary adenocarcinoma in Sprague-Dawley rats treated with 7,12-dimethylbenz(alpha)-anthracene (DMBA) were investigated." | 3.66 | Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. ( Chabner, B; Cohen, M; Lippman, M; Reichert, C; Roselle, D; Tamarkin, L, 1981) |
| "Melatonin is an indolic hormone produced mainly by the pineal gland." | 2.42 | Melatonin and mammary cancer: a short review. ( Cos, S; Fernández, R; Mediavilla, MD; Sánchez-Barceló, EJ, 2003) |
| "Melatonin treatment significantly inhibited the growth of LNCaP cells in a dose- and time-dependent manner." | 1.35 | Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. ( Joo, SS; Yoo, YM, 2009) |
| "Pretreatment with luzindole, which is a selective melatonin receptor antagonist, prior to the addition of melatonin also blocked the inhibitory effect of melatonin on Ishikawa cells." | 1.31 | Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. ( Ishizuka, B; Kanishi, Y; Kobayashi, Y; Noda, S; Saito, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cos, S | 3 |
| González, A | 2 |
| Martínez-Campa, C | 2 |
| Mediavilla, MD | 3 |
| Alonso-González, C | 2 |
| Sánchez-Barceló, EJ | 3 |
| Joo, SS | 1 |
| Yoo, YM | 1 |
| Hill, SM | 4 |
| Frasch, T | 1 |
| Xiang, S | 1 |
| Yuan, L | 3 |
| Duplessis, T | 1 |
| Mao, L | 1 |
| Siegfried, JM | 1 |
| Bukowska, A | 1 |
| Erren, TC | 3 |
| Fernández, R | 1 |
| Sahar, S | 1 |
| Sassone-Corsi, P | 1 |
| Byrns, MC | 1 |
| Steckelbroeck, S | 1 |
| Penning, TM | 1 |
| Sanchez-Mateos, S | 1 |
| Tamarkin, L | 1 |
| Cohen, M | 1 |
| Roselle, D | 1 |
| Reichert, C | 1 |
| Lippman, M | 1 |
| Chabner, B | 1 |
| Baldwin, WS | 1 |
| Barrett, JC | 1 |
| Eck, KM | 1 |
| Duffy, L | 1 |
| Ram, PT | 1 |
| Ayettey, S | 1 |
| Chen, I | 1 |
| Cohn, CS | 1 |
| Reed, JC | 1 |
| Lupowitz, Z | 1 |
| Zisapel, N | 1 |
| Piekarski, C | 1 |
| Kanishi, Y | 1 |
| Kobayashi, Y | 1 |
| Noda, S | 1 |
| Ishizuka, B | 1 |
| Saito, K | 1 |
| Xi, SC | 1 |
| Tam, PC | 1 |
| Brown, GM | 1 |
| Pang, SF | 1 |
| Shiu, SY | 1 |
| Stevens, RG | 1 |
| Collins, AR | 1 |
| Dai, J | 1 |
| Dubocovich, ML | 1 |
| Spriggs, LL | 1 |
| Simon, MA | 1 |
| Muraoka, H | 1 |
| Blask, DE | 1 |
| Regelson, W | 1 |
| Pierpaoli, W | 1 |
8 reviews available for melatonin and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Melatonin as a selective estrogen enzyme modulator.
Topics: 17-Hydroxysteroid Dehydrogenases; Aromatase; Breast Neoplasms; Estrogens; Humans; Melatonin; Neoplas | 2008 |
[Anticarcinogenic role of melatonin--potential mechanisms].
Topics: Animals; Anticarcinogenic Agents; Antioxidants; Evidence-Based Medicine; Humans; Melatonin; Neoplasm | 2011 |
Does light cause internal cancers? The problem and challenge of an ubiquitous exposure.
Topics: Environmental Exposure; Humans; Light; Melatonin; Neoplasms, Hormone-Dependent | 2002 |
Melatonin and mammary cancer: a short review.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Melatonin; Mice; Neoplasms, Hormon | 2003 |
Circadian clock and breast cancer: a molecular link.
Topics: Acetylation; Animals; ARNTL Transcription Factors; Basic Helix-Loop-Helix Transcription Factors; Bre | 2007 |
Melatonin: receptor-mediated events that may affect breast and other steroid hormone-dependent cancers.
Topics: Breast Neoplasms; Electromagnetic Fields; Humans; Melatonin; Neoplasms, Hormone-Dependent; Receptors | 1998 |
[Light, melatonin and internal cancers - recent facts and research perspectives].
Topics: Animals; Causality; Circadian Rhythm; Humans; Light; Melatonin; Neoplasms, Hormone-Dependent; Risk F | 2002 |
Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors; sex steroid metabolism, immunologic response, and chronobiologic factors in tumor growth and therapy.
Topics: Animals; Antineoplastic Agents; Chronobiology Phenomena; Gonadal Steroid Hormones; Humans; Melatonin | 1987 |
13 other studies available for melatonin and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer.
Topics: Analysis of Variance; Apoptosis; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP | 2009 |
Molecular mechanisms of melatonin anticancer effects.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Circadian Rhythm; Estrogen Receptor alpha; Female; Gene | 2009 |
Early changes in pulmonary gene expression following tobacco exposure shed light on the role of estrogen metabolism in lung carcinogenesis.
Topics: Alcohol Oxidoreductases; Animals; Aryl Hydrocarbon Hydroxylases; Cell Transformation, Neoplastic; Ci | 2010 |
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone indepe
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anti-Inflammatory Agents, N | 2008 |
Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Cell Line, Tumor; Estrogens; Humans; Melatonin; | 2008 |
Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Benz(a)Anthracenes; Circadian Rhythm; Fem | 1981 |
A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Nor | 1998 |
Hormonal interactions in human prostate tumor LNCaP cells.
Topics: Androgens; Cell Division; Cell Survival; Drug Interactions; Estradiol; Humans; Male; Melatonin; Neop | 1999 |
Does winter darkness in the Artic protect against cancer? The melatonin hypothesis revisited.
Topics: Alaska; Arctic Regions; Breast Neoplasms; Canada; Darkness; Female; Greenland; Humans; Male; Melaton | 1999 |
Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Division; Endometrial Neoplasms; Estradiol; | 2000 |
Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells.
Topics: Adenocarcinoma; Blotting, Western; Calcium; Cell Division; Dihydrotestosterone; Dose-Response Relati | 2000 |
MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Division; Estrogen Receptor alpha; Estrogens; Female; Gene Ex | 2002 |
The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Interactions; Estrogen Antagonists; Est | 1992 |